{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:08:25Z","timestamp":1788930505735,"version":"build-2803163510"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Department of Science and Technology of Hunan Province","doi-asserted-by":"publisher","award":["2025JK2004"],"award-info":[{"award-number":["2025JK2004"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Program of China","award":["2023ZD0506105"],"award-info":[{"award-number":["2023ZD0506105"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02748-w","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:13:17Z","timestamp":1785485597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ecosystem-matched reprogramming of the tumor\u2013immune microenvironment to overcome cancer immunotherapy resistance"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaodong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songjiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"8","key":"2748_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"26","key":"2748_CR2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"26","key":"2748_CR3","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"19","key":"2748_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"9","key":"2748_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"7559","key":"2748_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231\u20135.","journal-title":"Nature"},{"issue":"6230","key":"2748_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"6","key":"2748_CR8","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren L, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373\u2013e138719.","journal-title":"Cell"},{"issue":"10","key":"2748_CR9","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"2748_CR10","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1172\/JCI79434","volume":"126","author":"AW Lund","year":"2016","unstructured":"Lund AW, et al. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016;126(9):3389\u2013402.","journal-title":"J Clin Invest"},{"issue":"7693","key":"2748_CR11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"4","key":"2748_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"1","key":"2748_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025;10(1):227.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2748_CR14","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.","journal-title":"Nat Commun"},{"issue":"7822","key":"2748_CR15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris ST, et al. cDC1 prime and are licensed by CD4\u2009+\u2009T cells to induce anti-tumour immunity. Nature. 2020;584(7822):624\u20139.","journal-title":"Nature"},{"issue":"1","key":"2748_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41467-025-55969-w","volume":"16","author":"M Sun","year":"2025","unstructured":"Sun M, et al. Lymphatic-derived oxysterols promote anti-tumor immunity and response to immunotherapy in melanoma. Nat Commun. 2025;16(1):1217.","journal-title":"Nat Commun"},{"issue":"1","key":"2748_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136.","journal-title":"Nat Commun"},{"issue":"2","key":"2748_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201.","journal-title":"Cancer Discov"},{"issue":"1","key":"2748_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"key":"2748_CR20","doi-asserted-by":"crossref","unstructured":"Banta, K.L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8\u2009<\u2009sup>+\u2009T\u00a0cell responses. Immunity. 2022;55(3):512\u2013526.e9.","DOI":"10.1016\/j.immuni.2022.02.005"},{"issue":"5","key":"2748_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","volume":"23","author":"J Gao","year":"2017","unstructured":"Gao J, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551\u20135.","journal-title":"Nat Med"},{"issue":"1","key":"2748_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41698-021-00200-4","volume":"5","author":"G Wang","year":"2021","unstructured":"Wang G, et al. The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. npj Precision Oncol. 2021;5(1):56.","journal-title":"npj Precision Oncol"},{"issue":"9","key":"2748_CR23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","volume":"23","author":"M Musella","year":"2022","unstructured":"Musella M, et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat Immunol. 2022;23(9):1379\u201392.","journal-title":"Nat Immunol"},{"issue":"7519","key":"2748_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559\u201363.","journal-title":"Nature"},{"issue":"6","key":"2748_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1084\/jem.193.6.727","volume":"193","author":"EY Lin","year":"2001","unstructured":"Lin EY, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727\u201340.","journal-title":"J Exp Med"},{"issue":"19","key":"2748_CR26","doi-asserted-by":"publisher","first-page":"7465","DOI":"10.1158\/0008-5472.CAN-10-1439","volume":"70","author":"AL Doedens","year":"2010","unstructured":"Doedens AL, et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010;70(19):7465\u201375.","journal-title":"Cancer Res"},{"issue":"16","key":"2748_CR27","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez PC, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-Cell responses. Cancer Res. 2004;64(16):5839\u201349.","journal-title":"Cancer Res"},{"issue":"11","key":"2748_CR28","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, et al. HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439\u201353.","journal-title":"J Exp Med"},{"issue":"9","key":"2748_CR29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"2748_CR30","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ni1536","volume":"8","author":"P Pandiyan","year":"2007","unstructured":"Pandiyan P, et al. CD4\u2009+\u2009CD25+Foxp3\u2009+\u2009regulatory T cells induce cytokine deprivation\u2013mediated apoptosis of effector CD4\u2009+\u2009T cells. Nat Immunol. 2007;8(12):1353\u201362.","journal-title":"Nat Immunol"},{"issue":"13","key":"2748_CR31","first-page":"3128","volume":"59","author":"S Onizuka","year":"1999","unstructured":"Onizuka S, et al. Tumor rejection by in vivo administration of anti-CD25 (Interleukin-2 Receptor \u03b1) monoclonal antibody. Cancer Res. 1999;59(13):3128\u201333.","journal-title":"Cancer Res"},{"issue":"7528","key":"2748_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"issue":"5","key":"2748_CR33","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638\u201352.","journal-title":"Cancer Cell"},{"issue":"4","key":"2748_CR34","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H, et al. Expansion and activation of CD103\u2009<\u2009sup>+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924\u201338.","journal-title":"Immunity"},{"issue":"6","key":"2748_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719\u201334.","journal-title":"Cancer Cell"},{"issue":"5706","key":"2748_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"issue":"10","key":"2748_CR37","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang Y, et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"2748_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41698-021-00197-w","volume":"5","author":"Y Boucher","year":"2021","unstructured":"Boucher Y, et al. Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. npj Precision Oncol. 2021;5(1):62.","journal-title":"npj Precision Oncol"},{"issue":"407","key":"2748_CR39","doi-asserted-by":"publisher","first-page":"eaal4712","DOI":"10.1126\/scitranslmed.aal4712","volume":"9","author":"M Fankhauser","year":"2017","unstructured":"Fankhauser M, et al. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Sci Transl Med. 2017;9(407):eaal4712.","journal-title":"Sci Transl Med"},{"issue":"29","key":"2748_CR40","doi-asserted-by":"publisher","first-page":"45789","DOI":"10.18632\/oncotarget.9953","volume":"7","author":"ES Steinskog","year":"2016","unstructured":"Steinskog ES, et al. Impaired lymphatic function accelerates cancer growth. Oncotarget. 2016;7(29):45789\u2013802.","journal-title":"Oncotarget"},{"issue":"6","key":"2748_CR41","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"key":"2748_CR42","doi-asserted-by":"crossref","unstructured":"Elia, I, et al. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8\u2009<\u2009sup>+\u2009T\u00a0cells. Cell Metabolism. 2022;34(8):1137\u20131150.e6.","DOI":"10.1016\/j.cmet.2022.06.008"},{"issue":"4","key":"2748_CR43","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young A, et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 2018;78(4):1003\u201316.","journal-title":"Cancer Res"},{"key":"2748_CR44","doi-asserted-by":"crossref","unstructured":"Gu J, et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-\u03b2 signaling in regulatory T\u00a0cells. Cell Reports. 2022;39(12):110986.","DOI":"10.1016\/j.celrep.2022.110986"},{"issue":"3","key":"2748_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell. 2016;30(3):391\u2013403.","journal-title":"Cancer Cell"},{"key":"2748_CR46","doi-asserted-by":"crossref","unstructured":"Niu H, et al. LKB1 prevents ILC2 exhaustion to enhance antitumor immunity. Cell Rep. 2024;43(5):113579.","DOI":"10.1016\/j.celrep.2023.113579"},{"issue":"7","key":"2748_CR47","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41590-021-00943-z","volume":"22","author":"N Jacquelot","year":"2021","unstructured":"Jacquelot N, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22(7):851\u201364.","journal-title":"Nat Immunol"},{"issue":"8","key":"2748_CR48","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/j.celrep.2020.01.103","volume":"30","author":"M Wagner","year":"2020","unstructured":"Wagner M, et al. Tumor-derived lactic acid contributes to the paucity of intratumoral ILC2s. Cell Rep. 2020;30(8):2743\u2013e27575.","journal-title":"Cell Rep"},{"issue":"7629","key":"2748_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature. 2016;539(7629):443\u20137.","journal-title":"Nature"},{"issue":"7629","key":"2748_CR50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM, et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature. 2016;539(7629):437\u201342.","journal-title":"Nature"},{"issue":"4","key":"2748_CR51","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.cell.2018.09.030","volume":"175","author":"MM Gubin","year":"2018","unstructured":"Gubin MM, et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175(4):1014\u2013e103019.","journal-title":"Cell"},{"issue":"10","key":"2748_CR52","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264\u201372.","journal-title":"Nat Med"},{"issue":"6","key":"2748_CR53","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846\u201359.","journal-title":"Cancer Cell"},{"issue":"6024","key":"2748_CR54","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612\u20136.","journal-title":"Science"},{"issue":"8","key":"2748_CR55","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell CB, et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomedical Eng. 2018;2(8):578\u201388.","journal-title":"Nat Biomedical Eng"},{"issue":"5","key":"2748_CR56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell B, et al. Macrophage IL-10 blocks CD8\u2009<\u2009sup>+\u2009t cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014;26(5):623\u201337.","journal-title":"Cancer Cell"},{"issue":"18","key":"2748_CR57","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057\u201369.","journal-title":"Cancer Res"},{"issue":"8","key":"2748_CR58","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","volume":"16","author":"PA Cassier","year":"2015","unstructured":"Cassier PA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8):949\u201356.","journal-title":"Lancet Oncol"},{"issue":"10197","key":"2748_CR59","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387.","journal-title":"Lancet"},{"issue":"5","key":"2748_CR60","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, et al. Low-dose irradiation programs macrophage differentiation to an iNOS\u2009<\u2009sup>+\/M1 phenotype that orchestrates effective t cell immunotherapy. Cancer Cell. 2013;24(5):589\u2013602.","journal-title":"Cancer Cell"},{"issue":"9","key":"2748_CR61","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson TR, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695\u2013710.","journal-title":"J Exp Med"},{"issue":"9","key":"2748_CR62","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.20130573","volume":"210","author":"Y Bulliard","year":"2013","unstructured":"Bulliard Y, et al. Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210(9):1685\u201393.","journal-title":"J Exp Med"},{"issue":"4","key":"2748_CR63","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","volume":"46","author":"F Arce Vargas","year":"2017","unstructured":"Arce Vargas F, et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity. 2017;46(4):577\u201386.","journal-title":"Immunity"},{"issue":"19","key":"2748_CR64","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","volume":"19","author":"MF Fransen","year":"2013","unstructured":"Fransen MF, et al. Controlled local delivery of CTLA-4 blocking antibody induces CD8\u2009+\u2009T-cell\u2013dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res. 2013;19(19):5381\u20139.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2748_CR65","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485\u201392.","journal-title":"N Engl J Med"},{"issue":"7","key":"2748_CR66","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105\u20132105.","journal-title":"J Clin Oncol"},{"issue":"5933","key":"2748_CR67","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457\u201361.","journal-title":"Science"},{"issue":"3","key":"2748_CR68","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418\u201329.","journal-title":"Cancer Cell"},{"issue":"50","key":"2748_CR69","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci. 2013;110(50):20212\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"2748_CR70","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735\u201347.","journal-title":"Cancer Cell"},{"issue":"27","key":"2748_CR71","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020;38(27):3185\u201394.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2748_CR72","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","volume":"36","author":"SR Hingorani","year":"2018","unstructured":"Hingorani SR, et al. HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018;36(4):359\u201366.","journal-title":"J Clin Oncol"},{"issue":"7693","key":"2748_CR73","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538\u201343.","journal-title":"Nature"},{"issue":"4","key":"2748_CR74","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320\u20139.","journal-title":"Nat Genet"},{"issue":"6","key":"2748_CR75","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss J, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287\u201395.","journal-title":"Clin Cancer Res"},{"issue":"424","key":"2748_CR76","doi-asserted-by":"publisher","first-page":"eaan5488","DOI":"10.1126\/scitranslmed.aan5488","volume":"10","author":"Y Lan","year":"2018","unstructured":"Lan Y, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci Transl Med. 2018;10(424):eaan5488.","journal-title":"Sci Transl Med"},{"issue":"20","key":"2748_CR77","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"24","key":"2748_CR78","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"6","key":"2748_CR79","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808\u201320.","journal-title":"Lancet Oncol"},{"issue":"3suppl","key":"2748_CR80","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","volume":"39","author":"RS Finn","year":"2021","unstructured":"Finn RS, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3suppl):267\u2013267.","journal-title":"J Clin Oncol"},{"issue":"385","key":"2748_CR81","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, et al. Combined antiangiogenic and anti\u2013PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679.","journal-title":"Sci Transl Med"},{"issue":"385","key":"2748_CR82","doi-asserted-by":"publisher","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel M, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):eaak9670.","journal-title":"Sci Transl Med"},{"issue":"2","key":"2748_CR83","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts EW, et al. Critical role for CD103+\/CD141\u2009+\u2009dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30(2):324\u201336.","journal-title":"Cancer Cell"},{"issue":"5","key":"2748_CR84","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688\u201392.","journal-title":"Nat Med"},{"issue":"7637","key":"2748_CR85","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"7","key":"2748_CR86","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018\u201330.","journal-title":"Cell Rep"},{"issue":"7662","key":"2748_CR87","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"issue":"6236","key":"2748_CR88","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803\u20138.","journal-title":"Science"},{"issue":"5796","key":"2748_CR89","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126\u20139.","journal-title":"Science"},{"issue":"6","key":"2748_CR90","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","volume":"9","author":"S-E Bentebibel","year":"2019","unstructured":"Bentebibel S-E, et al. A First-in-human study and biomarker analysis of NKTR-214, a novel IL2R\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 2019;9(6):711\u201321.","journal-title":"Cancer Discov"},{"issue":"1","key":"2748_CR91","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie K, et al. IL-15 Superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer. NEJM Evid. 2023;2(1):EVIDoa2200167.","journal-title":"NEJM Evid"},{"key":"2748_CR92","doi-asserted-by":"crossref","unstructured":"Naing A et al. PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8\u2009<\u2009sup>+\u2009T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell. 2018;34(5):775\u2013791.e3.","DOI":"10.1016\/j.ccell.2018.10.007"},{"issue":"6","key":"2748_CR93","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109\u2013e111910.","journal-title":"Cell"},{"issue":"1","key":"2748_CR94","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J Immunother Cancer. 2019;7(1):145.","journal-title":"J Immunother Cancer"},{"issue":"7662","key":"2748_CR95","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321.","journal-title":"Nature"},{"issue":"3","key":"2748_CR96","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney JA, et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41(3):528\u201340.","journal-title":"J Clin Oncol"},{"issue":"10427","key":"2748_CR97","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u201344.","journal-title":"Lancet"},{"issue":"12","key":"2748_CR98","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","volume":"26","author":"AP Algazi","year":"2020","unstructured":"Algazi AP, et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res. 2020;26(12):2827\u201337.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2748_CR99","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319(25):1676\u201380.","journal-title":"N Engl J Med"},{"issue":"24","key":"2748_CR100","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656\u201366.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2748_CR101","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12):e005755.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2748_CR102","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363.","journal-title":"Cancer Discov"},{"issue":"9","key":"2748_CR103","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2748_CR104","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2748_CR105","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083\u201397.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2748_CR106","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho BC, et al. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1\u2013high advanced NSCLC: a randomized, open-label, phase 3 trial. J Thorac Oncol. 2023;18(12):1731\u201342.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2748_CR107","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392.","journal-title":"Lancet Oncol"},{"issue":"6411","key":"2748_CR108","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science. 2018;362(6411):eaar3593.","journal-title":"Science"},{"issue":"6","key":"2748_CR109","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845\u2013e8657.","journal-title":"Cancer Cell"},{"issue":"4","key":"2748_CR110","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998\u2013e101320.","journal-title":"Cell"},{"issue":"7","key":"2748_CR111","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948\u201360.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2748_CR112","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649\u201354.","journal-title":"Nat Med"},{"issue":"7577","key":"2748_CR113","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249\u201353.","journal-title":"Nature"},{"issue":"8","key":"2748_CR114","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00262-021-02861-3","volume":"70","author":"SA O\u2019Brien","year":"2021","unstructured":"O\u2019Brien SA, et al. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment. Cancer Immunol Immunother. 2021;70(8):2401\u201310.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2748_CR115","doi-asserted-by":"publisher","first-page":"e0291772","DOI":"10.1371\/journal.pone.0291772","volume":"18","author":"K Fujikawa","year":"2023","unstructured":"Fujikawa K, et al. Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors. PLoS ONE. 2023;18(9):e0291772.","journal-title":"PLoS ONE"},{"issue":"10","key":"2748_CR116","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.immuni.2021.09.005","volume":"54","author":"MD Sharma","year":"2021","unstructured":"Sharma MD, et al. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. Immunity. 2021;54(10):2354\u2013e23718.","journal-title":"Immunity"},{"key":"2748_CR117","doi-asserted-by":"crossref","unstructured":"Kokolus KM, et al. Synergy between TLR3-ligand and IFN-\u03b1 in the transient sensitization of Cold tumors to PD-1 blockade and the induction of systemic immunity. J Immunother Cancer. 2025;13(9):e012307.","DOI":"10.1136\/jitc-2025-012307"},{"issue":"4","key":"2748_CR118","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","volume":"58","author":"M-R Benmebarek","year":"2025","unstructured":"Benmebarek M-R, et al. Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity. 2025;58(4):926\u2013e94510.","journal-title":"Immunity"},{"issue":"10","key":"2748_CR119","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.ajpath.2019.06.010","volume":"189","author":"M Wagner","year":"2019","unstructured":"Wagner M, Steinskog ES, Wiig H. Blockade of lymphangiogenesis shapes tumor-promoting adipose tissue inflammation. Am J Pathol. 2019;189(10):2102\u201314.","journal-title":"Am J Pathol"},{"key":"2748_CR120","doi-asserted-by":"crossref","unstructured":"Huang Q et al. Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival. Cancers (Basel), 2021. 13(3).","DOI":"10.3390\/cancers13030559"},{"key":"2748_CR121","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bbrc.2022.11.006","volume":"637","author":"Y Okuyama","year":"2022","unstructured":"Okuyama Y, et al. IL-33-ILC2 axis promotes anti-tumor CD8\u2009+\u2009T cell responses via OX40 signaling. Biochem Biophys Res Commun. 2022;637:9\u201316.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2748_CR122","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"2748_CR123","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta KL, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity. 2022;55(3):512\u2013e5269.","journal-title":"Immunity"},{"issue":"3","key":"2748_CR124","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar R, et al. NK Cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res. 2019;7(3):363\u201375.","journal-title":"Cancer Immunol Res"},{"key":"2748_CR125","doi-asserted-by":"publisher","first-page":"122253","DOI":"10.1016\/j.biomaterials.2023.122253","volume":"301","author":"M Yang","year":"2023","unstructured":"Yang M, et al. Synchronous targeted delivery of TGF-\u03b2 siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment. Biomaterials. 2023;301:122253.","journal-title":"Biomaterials"},{"issue":"6","key":"2748_CR126","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/aps.2017.44","volume":"38","author":"J-j Sun","year":"2017","unstructured":"Sun J-j, et al. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. Acta Pharmacol Sin. 2017;38(6):823\u201334.","journal-title":"Acta Pharmacol Sin"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02748-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02748-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02748-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:37:39Z","timestamp":1788928659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02748-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02748-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"211"}}